Featured News

Consider joining the LILY Study, a phase 1 clinical trial for people with celiac disease investigating DONQ52, a new potential celiac disease treatment.

iCureCeliac® is the Foundation’s patient-powered tool that is the single best resource for celiac disease researchers around the world helping to accelerate the search for treatments and a cure.

The risk of developing CAD in celiac patients was found to be higher for white males, and patients with celiac disease and CAD are more likely to have disorders such as high cholesterol, type 2 diabetes, and iron-deficiency anemia.  

Last week in Washington, D.C., the Celiac Disease Foundation and our allies secured two critical wins in our mission to drive policy change to improve the health of those living with celiac disease.

New research studying the association of celiac disease and inflammatory bowel disease (IBD) shows a strong relationship between the two conditions.

Curing Celiac: A Short Story, a new film by Hayley Repton, encourages patients to join the iCureCeliac® patient registry, the single best patient-centered resource for celiac disease researchers in the world.

An analysis by an independent statistician of the ongoing Phase 3 trial for Larazotide has concluded that a substantial number of new patients would have to be added to the existing trial in order to get scientifically meaningful results.

Last week, the Celiac Disease Foundation, as part of The Defense Health Research Consortium, co-signed a letter requesting a budget increase for the Congressionally Directed Medical Research Programs.

The FDA released the long-awaited draft guidance, “Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet."

According to a recent analysis, children who have a first-degree relative with celiac disease may be at higher risk of developing the disease before age 10 than previously thought.